Precision Medical Care Newsletter - May 2025
May 2025 Newsletter
Dr Catherine is back from the Lisbon Longevity Summit, some notable “pearls:”
“Loneliness and social isolation = equivalent to smoking 15 cigarettes/daily!”
“THE FUTURE IS NOT SOMETHING THAT HAPPENS IT IS SOMETHING THAT WE CREATE”
“Nature itself is the best medicine. The physician treats but nature heals” Hippocrates
“Once you get rich, it’s really tough to consume all your wealth. So every year you stay alive, you get richer, right? So it’s in your best interest to invest in expanding and increasing your lifespan.”
“Why retire when you can rewire?”
“Four goals of regenerative medicine:
1. High performance mobility
2. High performance cognitive function
3. High performance immunity
4. Youthful aesthetics”“AI will advance opportunities for everyone to have access to realtime personalized health coaches.”
“Do it for the billions, not just for a few billionaires.”
“Predictive medical forecasting: There’s a big tussle now between the pace of advance and the alignment of human values.”
“Chronic fatigue patients cannot really relax because for relaxing, you also need much mitochondrial energy, when it’s depleted, this is neurodegeneration.”
The future of “longevity” is evident in the transitions and trends in real estate and hotel development:
This is a summary slide of how the term “spa “ will now be “wellness, healthy longevity” at most resorts with focus on diagnostics and therapeutics:
Luxury Wellness Medical Tourism is in demand, especially for adults over age 55.
Here is an example of how the science of therapeutic fasting in incorporated into a wellness week at a top tier destination resort for a wellness retreat (Six Senses Ibiza):
Therapeutic fasting retreats are medically supervised at the Buchinger Wilhelmi resort clinics. The physicians and scientists there are checking labs and imaging scans to confirm the client’s tremendous health improvements which align with the longevity benefits:
“Precision Wellness” is the future messaging of luxury lounges and retreats with health “treatment and experience stacking.”
Women’s health and Cellular Medicine topics were all highlights of the conference, too. More updates to come!
Join us next week with one of our Precision Physician Partners, Dr Michael Davidson. He is the chief of clinical lipidology at the University of Chicago and he will be speaking on menopause and impacts on lipid and cardiovascular disease risks: next week May 21 at 6pm. HERE is the link to the zoom session.
Dr. Catherine with longevity physician colleagues Dr. Felice Gersh, Dr. Mayoni Goonerante, Dr. Rory Melville, Dr. Elizabeth Yurth and Dr. Abid Husain.
GLP-1s Gaining Attention for Neuroprotective Effects
Medications like semaglutide (a GLP-1 receptor agonist) are gaining attention not only for their metabolic benefits but also for potential neuroprotective effects. Recent studies suggest they may reduce dementia risk by up to 33% in individuals with type 2 diabetes.
These medications primarily act by improving glucose metabolism and energy regulation throughout the body and brain. Additionally, emerging evidence points to direct brain-protective mechanisms, potentially including:
• Reduced neuroinflammation.
• Enhanced neurogenesis and synaptic plasticity.
• Protection against neuronal cell death and excitotoxicity.
• Improved glymphatic clearance of neurotoxic proteins.
Optimizing glucose control remains foundational for brain health, but pharmacology isn't the only pathway. Non-pharmacological strategies, including dietary modifications, consistent exercise, and quality sleep, represent accessible and evidence-based approaches to achieving similar protective effects.
Newer studies on these medications suggest that our view of them shouldn't be limited to weight loss or blood sugar control—they've been shown to lower the risk of kidney disease, diabetes, fatty liver disease, and cardiovascular disease. Some studies even show that users of weight-loss drugs reduce their alcohol intake.
The latest evidence positions "anti-obesity" drugs as a compelling treatment for lowering the risk of age-related cognitive impairment, dementia, and Alzheimer's disease, especially because there are currently no effective drug treatments for these conditions (exercise, a healthy lifestyle, and genetic risk factors remain the most powerful contributors).
A recent study found that adults taking GLP-1RAs ()(including but not limited to Semaglutide) had a 33% lower risk of developing Alzheimer's disease and related dementias compared to adults taking other glucose-lowering medications. Adults taking another type of glucose-lowering medication known as a sodium glucose cotransporter 2 inhibitor (SGLT2i) had a similar 43% reduction in dementia or Alzheimer's disease risk.Podcast Recommendations
Blood based biomarker testing for Alzheimer’s
Dr Rachel Rubin on Dr Attia’s podcast, Menopause myths & facts
Bone health through menopausal transition
The Scam Behind "Longevity Experts" | Dr. Eric Topol
Book Recommendations
Super Agers: An Evidence-Based Approach to Longevity by Dr. Eric Topol, this is an outstanding book!
Precision Medicine and AI
The future of medicine with AI data integration and interpretation from our fragmented health system to offer diagnostic insights and therapeutic options:
